# Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

> **NCT05081180** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Central Nervous System Tumors

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05081180
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-03
- **Primary completion:** 2026-02-11
- **Final completion:** 2026-05-29
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05081180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05081180, "Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05081180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*